Sitagliptin CAS 486460-32-6 Puritas >99.0% (HPLC) API Factory High Purity Featured Image

Sitagliptin CAS 486460-32-6 Munditia >99.0% (HPLC) API Factory

Description:

Chemical Name: Sitagliptin

CAS: 486460-32-6

Puritas: >99.0% (HPLC)

Aspectus: Alba ad Off-White Crystalline pulveris

Sitagliptin ad treatment of type II diabete mellitus

High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com

Mitte ad nos inscriptio

Product Detail

Product Tags

Descriptio:

Supple Sitagliptin Phosphate Monohydratorum intermedia:
Sitagliptin API CAS 486460-32-6
Sitagliptin Phosphate Monohydratum API CAS 654671-77-9
Acidum trifluorophenylaceticum 2,4,5-
Boc-(R)-3-Amino-4-(2,4,5-Trifluoro-Phenyl)-Butyric Acidum CAS 486460-00-8
Sitagliptin Triazole Hydrochloride CAS 762240-92-6
Sitagliptin Phosphate Monohydratum Intermediate CAS 486460-21-3

Chemical Properties:

Nomen chemicum	Sitagliptin
Synonyma	(3R) -3-Amino-1-[3-(trifluoromethyl)-5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a]pyrazin-7-yl]-4- (2,4,5-trifluoropheyl)butan-1-one
CAS Number	486460-32-6
Stock Status	In Stock, Productio Ascendite ad Tons
Formulae hypotheticae	C16H15F6N5O
M. Pondus	407.31
Liquescens punctum	114.0~115.0℃
Brand	Ruifu Chemical

Specifications:

Item	Specifications
Aspectus	Alba ad Off-White Crystalline pulveris
Lepidium sativum ab HPLC	Retentionis tempus Sample concordat cum Reference Standard
Damnum in Siccatio	<1.0%
Residere in Ignition	<0.20%
Substantiae cognatae
Unam immunditiam	<0.50%
Totalis immunditias	<1.0%
Puritas	>99.0% (HPLC)
Puritas Enantiomeric	<0.50%
Metalla gravis	<20ppm
Test Standard	Enterprise Standard
Consuetudinem	API;Typus II Diabetes Mellitus

Sarcina & Repono:

sarcina: Utrem, aluminium foil, sacculum, 25kg/cardboard Drum, vel secundum exigentiam emptoris.

Repono Condition:Repone in vasis signatis in loco frigido et sicco;A luce et humore protege.

commoda:

FAQ:

Applicatio:

Sitagliptin (CAS: 486460-32-6), ut novum genus pharmaci antidiabetici, Sitagliptin phosphas commoda dependentiae glucose habet, effectum hypoglycemicum moderatum, excrementum sine hypoglycemia auctum, efficaciter famem allevians, nec latus effectus nauseam habuit; vomitus, hydropicus et auctus pondus corporis.Sitagliptin phosphas sicut unicum medicamentum curationis in aegris cum II diabete typus potest signanter reducere gradum hemoglobini glycosylati (HbA1c).Dipeptidylus peptidase-4 (DPP-4) inhibitor est, quae facultatem corporis humani ad summum sanguinem glucosum gradum minuendi emendare potest.Sitagliptin a Merck & Co evoluta est et probata usui medicorum in Iunctus Civitas MMVI.